Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Anticounterfeiting PSA Urges Public To Verify Web Pharmacy Licensure

Executive Summary

An FDA counterfeit drugs 1public service announcement directs consumers to look for the "Verified Internet Pharmacy Practice Sites" seal when purchasing drugs on the internet

You may also be interested in...



HDMA joins FDA counterfeit alert network

The Healthcare Distribution Management Association has joined FDA's counterfeit alert network. As a member of the network, the wholesaler group will distribute time-sensitive FDA messages and information on specific counterfeit incidents to member companies. It will also provide educational messages about counterfeit drugs, as well as information needed to recognize and report suspect or counterfeit drug products. FDA announced the creation of the counterfeit alert network when it released its "Combating Counterfeit Drugs" report in 2004 (1"The Pink Sheet" Feb. 23, 2004, p. 17). Other members of the network include the Academy of Managed Care Pharmacy, the National Association of Chain Drug Stores and the National Community Pharmacists Association...

HDMA joins FDA counterfeit alert network

The Healthcare Distribution Management Association has joined FDA's counterfeit alert network. As a member of the network, the wholesaler group will distribute time-sensitive FDA messages and information on specific counterfeit incidents to member companies. It will also provide educational messages about counterfeit drugs, as well as information needed to recognize and report suspect or counterfeit drug products. FDA announced the creation of the counterfeit alert network when it released its "Combating Counterfeit Drugs" report in 2004 (1"The Pink Sheet" Feb. 23, 2004, p. 17). Other members of the network include the Academy of Managed Care Pharmacy, the National Association of Chain Drug Stores and the National Community Pharmacists Association...

FDA Anticounterfeiting Business Practices Seem To Be Met By NABP Rules

The National Association of Boards of Pharmacy1 Model Rules for the Licensure of Wholesale Distributors appear to satisfy FDA's call for stakeholders to develop secure business practices

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel